The Nicotine–Parkinson’s Paradox

Nicotine is having a strange second life. Smoking has been falling for decades, but nicotine is moving the other way. Smoke-free pouches are everywhere and the clams are escalating from stimulant to nootropic to something that might protect the brain. The idea did not start with the wellness industry. It started inside the case against cigarettes. In 1959, the United States Public Health Service sorted years of American deaths by cause. Smokers were dying more from almost everything, but one line did not fit. The disease was then called paralysis agitans, and we call it Parkinson's now.

Among regular smokers, there were nine deaths from it, were the tables predicted around 25. Statistically speaking, nine deaths is almost nothing. It should have vanished the moment anyone looked harder. People looked harder for 65 years, and the signal never went away. What nobody could do was explain it. A cigarette contains thousands of compounds, and no one has been able to say which of them mattered or whether any of them did. The products people are buying now have removed almost all of them. What they kept is nicotine.

So we finally asked the question, all of it has been circling, which is not whether smokers get less Parkinson's, but whether nicotine is the reason why. I am William Wallace, and this is the Active Site. The clue itself was attacked almost immediately. In 1971, researchers pointed out that Parkinson's develops quietly years before anyone notices a tremor, which means the disease could be changing who smokes long before anyone knows they are ill. That reverse causation explanation is still the strongest alternative in this story.

It would have made sense for the argument to end there, but it did not. Through the 1970s and 1980s, case control studies kept finding the same thing. People with Parkinson's had smoked less than their neighbors, then came at prospective cohorts, which recorded smoking habits years before anyone got sick. The design's reverse causation should defeat. Pattern held there too, and by 2019, a European cohort following more than 200,000 people found current smokers developing Parkinson's at roughly half the rate of never smokers.

There was a second problem, and it went at nicotine directly. In 1981, epidemiologists reasoned that if nicotine protects, more nicotine should protect more. They estimated lifetime nicotine exposure in smokers who developed Parkinson's and smokers who did not, and the totals were nearly identical. There was also a way to narrow it without a laboratory, and that was to take the smoke out. In 2017, researchers pulled seven longstanding Swedish studies covering almost 350,000 men and looked only at those who had never smoked cigarettes.

Among them, use of snus, the Swedish smokeless tobacco, was associated with about a 60% lower rate of Parkinson's disease. A separate line of work found the same direction in people getting small amounts of nicotine from peppers, tomatoes, and potatoes, though that signal was weaker and only showed up in women. Cigarette smoke was out of the comparison and the association survived. But the epidemiology had gone as far as it could, and the question had to move into a laboratory. The formal hypothesis arrived in 1988 from the National Institute of Mental Health, and it was simple enough to state in a line, Parkinson's destroys dopamine neurons, and nicotine acts on them.

The first direct test actually made things worse. Mice were given nicotine and a toxin that kills dopamine neurons, and nicotine increased the damage. The authors wrote that the result was not compatible with nicotine being the protective component of smoke. One laboratory found the opposite. It belonged to a pharmacologist named Maryka Quik, who was working on the receptors nicotine axon, which sit directly on the dopamine neurons Parkinson's kills. Through the 1990s and 2000s, her group protected dopamine signaling in rats and then in monkeys.

Pattern was strange but consistent, reproducible in rats and primates, failing specifically in mice. Her strongest primate results deserve a little bit of precision here. Nicotine did not keep the dopamine neurons alive, and the cell bodies died anyways. What survived better were their nerve endings farther along the pathway. So by the mid-2000s, the animal case was real and narrower than the word protection suggests. What nobody had settled was what happened if it arrived afterward. Meanwhile, an entirely separate research line was building and it had nothing to do with Parkinson's.

Since the 1980s, psychiatric researchers had been asking what nicotine does to human cognition. Paul Newhouse published a single case in 1986, one Alzheimer's patient given nicotine intravenously, then a six-patient pilot. By the early 1990s, his group was running the question in reverse, blocking nicotine receptors in healthy adults and watching performance worsen. The definitive summary came in 2010 from the National Institute on Drug Abuse. A meta-analyses pulled 41 double-blind laboratory studies comparing nicotine with placebo, meaning neither participants nor researchers knew who was getting which.

The participants were healthy nonsmokers or smokers who had not been deprived, so the results cannot be dismissed as withdrawal relief. Across nine types of mental and motor performance, six improved, including detention, response speed, short-term memory accuracy, and fine motor control. The effects were modest, but they were real and they were reproducible. Three research lines had now accumulated and none of them depended on the others. An epidemiological clue that would not die, animal protection of dopamine function in some species, and real cognitive effects in human.

In 2012, Maryka Quik bound them together in the journal Movement Disorders under one title, Nicotine as a Potential Neuroprotective Agent for Parkinson's disease. That same year, the cognition line produced its strongest result. Newhouse and colleagues recruited 74 adults with amnestic mild cognitive impairment, meaning measurable memory loss that can precede Alzheimer's disease. None of them smoked and half received nicotine patches while half received placebo for six months. The main outcome was an attention task and nicotine improved it.

Several other measures moved in the same direction, although clinicians' overall judgment of whether patients were better did not clearly differ between groups. The word neuroprotection was now attached to the molecule, and the only way to test it was to run trials long enough to mean it. Two such trials were built, one in Parkinson's and one in memory. The Parkinson's trial was called NIC PD. It ran across 24 centers in Germany and the United States, funded by the Michael J. Fox Foundation. It recruited over 160 people diagnosed with Parkinson's within the previous 18 months, early enough that they had not yet started the usual dopamine-based drugs.

They received nicotine patches or placebo for one year. Then everyone stopped treatment for eight weeks before the main assessment, and that drug-free period is what makes the trial important. If nicotine merely improves symptoms, any benefit fades once the patches come off. If it slows the disease, the nicotine group should still be better off weeks later because less damage happened while they were treated. After six weeks, both groups had worsened. The placebo group worsened by about three and a half points on the Parkinson's rating scale.

The nicotine group worsened by about six. The difference was too uncertain to rule out chance, and it did not point toward protection either. There was a second measurement at 52 weeks while the patches were still on. The placebo group had worsened by about five points and the nicotine group by nine. Rules set before the trial began meant the number could not count as a formal finding. It still sits in the paper. In this case, nicotine did not show that it slowed Parkinson's and people who already had the disease. The memory trial was the other half and it had been running for years.

It was called MIND, standing for memory improvement through nicotine dosing, and it ran across 36 sites in the United States, funded by the National Institute of Aging. It enrolled close to 350 adults with mild cognitive impairment and gave them nicotine patches or placebo for two years. While it ran, Newhouse published a short review of the field he spent his career in. He called it Successes, Failures, and Future Prospects. That was 2019, the trial still years from finishing. It had originally been registered with an intention test as its main outcome, the kind of measure nicotine had improved before.

Before the study finished and before anyone knew who had received nicotine, that was changed to a word list memory test, which made the question harder. It was no longer whether nicotine improves performance while someone is taking it, but whether two years of it slows decline. The result was reported in December 2025. There was no clear difference on the main memory outcome and no clear difference in clinicians' overall assessment of patients. Those results have been presented publicly, but not yet published in a peer-reviewed paper.

So they have not been through the process that NIC-PD went through. Neither demonstrated the durable protection that the word neuroprotection implies. Taken alone, those results look like the end of the neuroprotection case, but nicotine has been carrying three different claims under the same word, and those two long-duration trials directly tested only one of them. The first is performance enhancement, meaning whether nicotine makes some cognitive tasks easier while the drug is active. The answer is yes, by small amounts, especially for attention and response speed.

The second is disease modification, meaning whether nicotine slows the process once Parkinson's or measurable cognitive decline is already present. That is what the two long-duration human trials were trying to test, and neither showed it. The third is prevention, meaning whether exposure years before Parkinson's becomes clinically visible changes the probability that the disease ever develops. That is the claim the 1959 observation actually points toward, and the claim the Swedish snus data had already supported since 2017.

Neither trial went near it, and interestingly, somebody had already published the condition under which those trials would fail. In 2009, Quik's group published a result that was not about whether nicotine protects, but about when it has to arrive. They gave nicotine to rats before an injury to the dopamine system and to other rats only afterward once the damage was done. The ones treated beforehand held on to much more function. The ones treated afterward did not improve. The primate work pointed in the same direction.

They put the finding in the title. Nicotine is neuroprotective when administered before but not after nigrostriatal damage. The protocol for the Parkinson's trial was signed in August 2011, two years later. It builds its animal case on Quik's 2006 primate result, the one showing protection. 2009 paper is not in any of it. Not the protocol, not the appendix, not the published trial. That is not a scandal. In 2009 the question was unsettled, other laboratories had reported conflicting results, and the trial's designers were reading the same literature as everybody else.

But the trial that followed did what the 2009 paper said would not work, giving nicotine to people whose dopamine neurons were already dying. Dose is not the explanation either. The monkeys were protected at blood nicotine levels the authors described as ordinary for a cigarette smoker, not even at extreme doses. NIC-PD went up to 28 milligrams a day, more than the strongest patch on a pharmacy shelf. A separate French trial pushed nicotine to 90 milligrams a day and held it there for months. Neither slowed the disease.

And when NIC-PD reported its failure in 2023, the investigators wrote that if anyone ever attempted nicotine in Parkinson's again, it should be done in people who do not yet have the disease. Fourteen years and the field arrived back at the sentence in the title. None of that identifies nicotine as the cause of the lower Parkinson's rates. The strongest alternative explanation is still reverse causation. If the earliest changes of Parkinson's make nicotine less rewarding, people heading toward the disease would be less likely to start smoking or using snus and more likely to stop.

That alone would lower the Parkinson's rates among nicotine users, with nicotine possibly not doing much. Studies that measured smoking years before diagnosis, along with genetic analyses, make a purely behavioral explanation harder, but they do not eliminate it. snus removes smoke, not tobacco leaf. Other chemicals in the leaf remain possible, though none has comparable human evidence. One proposed effect of cigarette smoke is a slowing enzyme that breaks down dopamine that could contribute to the cigarette pattern, but it cannot explain snus.

The field of suspects has narrowed, but the culprit has not been fully identified. Keep the three claims separate, and here is what the evidence actually supports. Nicotine can improve a narrow set of cognitive and motor measures in healthy people while it's active. The effects are real, they are not simply relief from withdrawal, and they are generally small improvements. Nicotine has not shown that it slows Parkinson's after diagnosis or memory decline once impairment is present. The direct human evidence argues against it as a treatment once those processes are underway.

Prevention is something different entirely. The old signal survives when cigarette smoke is removed. A weaker version appears in estimates of nicotine from food, and the animal work published before the human trials shows nicotine helping before damage to the dopamine system, but not after. Nobody has shown in humans that isolated nicotine taken for years before symptoms appear prevents Parkinson's. The trial that would settle it needs very large numbers of healthy people followed for years, exposed throughout to something with drug level effects that impacts the heart and blood vessels while waiting for a disease to appear.

What has never been established is whether the 1988 hypothesis was ever right, whether nicotine itself, taken years before disease appears, is what lowers Parkinson's risk in humans. That is the part of the 1959 clue that is still unresolved. That is all for this episode. Thank you to everyone who made it to the end. If you learned something or found this useful, please like, subscribe, and comment wherever it is you watched or listened to this. Until next time, stay healthy.